Herpes simplex virus in solid organ transplantation

American Journal of Transplantation

Volumn 13, Issue SUPPL.4, 2013, Pages 121-127

  Wilck, M B ^a   Zuckerman, R A ^b  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^b DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

Author keywords

Prevention; transplantation; treatment

Indexed keywords

ACICLOVIR; CIDOFOVIR; FAMCICLOVIR; FOSCARNET; GANCICLOVIR; TRIFLURIDINE; VALACICLOVIR;

ARTICLE; GRAFT RECIPIENT; HERPES SIMPLEX VIRUS; HERPES SIMPLEX VIRUS 1; HERPES SIMPLEX VIRUS 2; HUMAN; INFECTION PREVENTION; KERATITIS; LUNG LAVAGE; ORGAN TRANSPLANTATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RISK FACTOR; SOLID ORGAN TRANSPLANTATION;

ANTIVIRAL AGENTS; HERPES SIMPLEX; HUMANS; ORGAN TRANSPLANTATION; RISK FACTORS;

EID: 84874878587     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.12105     Document Type: Article

References (67)

1. Schillinger JA, Xu F, Sternberg MR, et al. National seroprevalence and trends in herpes simplex virus type 1 in the United States, 1976-1994. Sex Transm Dis 2004; 31: 753-760.
2. Xu F, Sternberg MR, Kottiri BJ, et al. Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States. JAMA 2006; 296: 964-973.
3. Engelberg R, Carrell D, Krantz E, Corey L, Wald A,. Natural history of genital herpes simplex virus type 1 infection. Sex Transm Dis 2003; 30: 174-177.
4. Roberts CM, Pfister JR, Spear SJ, Increasing proportion of herpes simplex virus type 1 as a cause of genital herpes infection in college students. Sex Transm Dis 2003; 30: 797-800.
5. Wald A, Zeh JE, Selke SA, et al. Reactivation of genital herpes simplex virus type 2 infection in asymptomatic seropositive persons. N Engl J Med 2000; 342: 844-850.
6. Greenberg MS, Friedman H, Cohen SG, Oh SH, Laster L, Starr S,. A comparative study of herpes simplex infections in renal transplant and leukemic patients. J Infect Dis 1987; 156: 280-287.
7. Naraqi S, Jackson GG, Jonasson O, Yamashiroya HM,. Prospective study of prevalence, incidence, and source of herpesvirus infections in patients with renal allografts. J Infect Dis 1977; 136: 531-540.
8. Pettersson E, Hovi T, Ahonen J, et al. Prophylactic oral acyclovir after renal transplantation. Transplantation 1985; 39: 279-281.
9. Seale L, Jones CJ, Kathpalia S, et al. Prevention of herpesvirus infections in renal allograft recipients by low-dose oral acyclovir. JAMA 1985; 254: 3435-3438.
10. Singh N, Dummer JS, Kusne S, et al. Infections with cytomegalovirus and other herpesviruses in 121 liver transplant recipients: Transmission by donated organ and the effect of OKT3 antibodies. J Infect Dis 1988; 158: 124-131.
11. Basse G, Mengelle C, Kamar N, et al. Disseminated herpes simplex type-2 (HSV-2) infection after solid-organ transplantation. Infection 2008; 36: 62-64.
12. Dummer JS, Armstrong J, Somers J, et al. Transmission of infection with herpes simplex virus by renal transplantation. J Infect Dis 1987; 155: 202-206.
13. Goodman JL,. Possible transmission of herpes simplex virus by organ transplantation. Transplantation 1989; 47: 609-613.
14. Kusne S, Schwartz M, Breinig MK, et al. Herpes simplex virus hepatitis after solid organ transplantation in adults. J Infect Dis 1991; 163: 1001-1007.
15. Smyth RL, Higenbottam TW, Scott JP, et al. Herpes simplex virus infection in heart-lung transplant recipients. Transplantation 1990; 49: 735-739.
16. Cook SD,. Herpes simplex virus in the eye. Br J Ophthalmol 1992; 76: 365-366.
17. Inoue Y,. Immunological aspects of herpetic stromal keratitis. Semin Ophthalmol 2008; 23: 221-227.
18. Lowance D, Neumayer HH, Legendre CM, et al. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group. N Engl J Med 1999; 340: 1462-1470.
19. Corey L, Holmes KK,. Genital herpes simplex virus infections: Current concepts in diagnosis, therapy, and prevention. Ann Intern Med 1983; 98: 973-983.
20. Nichols WG, Boeckh M, Carter RA, Wald A, Corey L,. Transferred herpes simplex virus immunity after stem-cell transplantation: Clinical implications. J Infect Dis 2003; 187: 801-808.
21. Tang IY, Maddux MS, Veremis SA, Bauma WD, Pollak R, Mozes MF., Low-dose oral acyclovir for prevention of herpes simplex virus infection during OKT3 therapy. Transplant Proc 1989; 21: 1758-1760.
22. Buell C, Koo J., Long-term safety of mycophenolate mofetil and cyclosporine: A review. J Drugs Dermatol 2008; 7: 741-748.
23. Pliszczynski J, Kahan BD,. Better actual 10-year renal transplant outcomes of 80% reduced cyclosporine exposure with sirolimus base therapy compared with full cyclosporine exposure without or with concomittant sirolimus treatment. Transplant Proc 2011; 43: 3657-3668.
24. Brennan DC, Legendre C, Patel D, et al. Cytomegalovirus incidence between everolimus versus mycophenolate in de novo renal transplants: Pooled analysis of three clinical trials. Am J Transplant 2011; 11: 2453-2462.
25. Lafferty WE, Krofft S, Remington M, et al. Diagnosis of herpes simplex virus by direct immunofluorescence and viral isolation from samples of external genital lesions in a high-prevalence population. J Clin Microbiol 1987; 25: 323-326.
26. Pouletty P, Chomel JJ, Thouvenot D, Catalan F, Rabillon V, Kadouche J,. Detection of herpes simplex virus in direct specimens by immunofluorescence assay using a monoclonal antibody. J Clin Microbiol 1987; 25: 958-959.
27. Caviness AC, Oelze LL, Saz UE, Greer JM, Demmler-Harrison GJ,. Direct immunofluorescence assay compared to cell culture for the diagnosis of mucocutaneous herpes simplex virus infections in children. J Clin Virol 2010; 49: 58-60.
28. Wald A, Huang ML, Carrell D, Selke S, Corey L,. Polymerase chain reaction for detection of herpes simplex virus (HSV) DNA on mucosal surfaces: Comparison with HSV isolation in cell culture. J Infect Dis 2003; 188: 1345-1351.
29. Kimberlin DW, Lakeman FD, Arvin AM, et al. Application of the polymerase chain reaction to the diagnosis and management of neonatal herpes simplex virus disease. National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. J Infect Dis 1996; 174: 1162-1167.
30. Ramaswamy M, McDonald C, Smith M, et al. Diagnosis of genital herpes by real time PCR in routine clinical practice. Sex Transm Infect 2004; 80: 406-410.
31. Filen F, Strand A, Allard A, Blomberg J, Herrmann B,. Duplex real-time polymerase chain reaction assay for detection and quantification of herpes simplex virus type 1 and herpes simplex virus type 2 in genital and cutaneous lesions. Sex Transm Dis 2004; 31: 331-336.
32. Cone RW, Hobson AC, Brown Z, et al. Frequent detection of genital herpes simplex virus DNA by polymerase chain reaction among pregnant women. JAMA 1994; 272: 792-796.
33. Lakeman FD, Whitley RJ,. Diagnosis of herpes simplex encephalitis: Application of polymerase chain reaction to cerebrospinal fluid from brain-biopsied patients and correlation with disease. National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. J Infect Dis 1995; 171: 857-863.
34. Johnston C, Magaret A, Selke S, Remington M, Corey L, Wald A,. Herpes simplex virus viremia during primary genital infection. J Infect Dis 2008; 198: 31-34.
35. Berrington WR, Jerome KR, Cook L, Wald A, Corey L, Casper C,. Clinical correlates of herpes simplex virus viremia among hospitalized adults. Clin Infect Dis 2009; 49: 1295-1301.
36. Zuckerman RA,. The clinical spectrum of herpes simplex viremia. Clin Infect Dis 2009; 49: 1302-1304.
37. Martin ET, Krantz E, Gottlieb SL, et al. A pooled analysis of the effect of condoms in preventing HSV-2 acquisition. Arch Intern Med 2009; 169: 1233-1240.
38. Corey L, Wald A, Patel R, et al. Once-daily valacyclovir to reduce the risk of transmission of genital herpes. N Engl J Med 2004; 350: 11-20.
39. Fiddian P, Sabin CA, Griffiths PD,. Valacyclovir provides optimum acyclovir exposure for prevention of cytomegalovirus and related outcomes after organ transplantation. J Infect Dis 2002; 186 (Suppl 1): S110-S115.
40. Boeckh M, Kim HW, Flowers ME, Meyers JD, Bowden RA,. Long-term acyclovir for prevention of varicella zoster virus disease after allogeneic hematopoietic cell transplantation-A randomized double-blind placebo-controlled study. Blood 2006; 107: 1800-1805.
41. Erard V, Wald A, Corey L, Leisenring WM, Boeckh M,. Use of long-term suppressive acyclovir after hematopoietic stem-cell transplantation: Impact on herpes simplex virus (HSV) disease and drug-resistant HSV disease. J Infect Dis 2007; 196: 266-270.
42. Workowski KA, Berman SM,. Sexually transmitted diseases treatment guidelines. 2006. MMWR Recomm Rep 2006; 55: 1-94.
43. Conant MA, Schacker TW, Murphy RL, Gold J, Crutchfield LT, Crooks RJ,. Valaciclovir versus aciclovir for herpes simplex virus infection in HIV-infected individuals: Two randomized trials. Int J STD AIDS 2002; 13: 12-21.
44. Diaz-Mitoma F, Sibbald RG, Shafran SD, Boon R, Saltzman RL,. Oral famciclovir for the suppression of recurrent genital herpes: A randomized controlled trial. Collaborative Famciclovir Genital Herpes Research Group. JAMA 1998; 280: 887-892.
45. Schacker TW, Hu HL, Koelle DM, et al. Famciclovir for the suppression of symptomatic and asymptomatic herpes simplex virus reactivation in HIV-infected persons. A double-blind, placebo-controlled trial. Ann Intern Med 1998; 128: 21-28.
46. American Academy of Pediatrics. Herpes Simplex. In:, Pickering LK, ed. Red Book: 2009 Report of the Committee on Infectious Diseases. 28th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2009: 363-373.
47. Chou S, Gallagher JG, Merigan TC,. Controlled clinical trial of intravenous acyclovir in heart-transplant patients with mucocutaneous herpes simplex infections. Lancet 1981; 1: 1392-1394.
48. Meyers JD, Wade JC, Mitchell CD, et al. Multicenter collaborative trial of intravenous acyclovir for treatment of mucocutaneous herpes simplex virus infection in the immunocompromised host. Am J Med 1982; 73: 229-235.
49. VanLandingham KE, Marsteller HB, Ross GW, Hayden FG,. Relapse of herpes simplex encephalitis after conventional acyclovir therapy. JAMA 1988; 259: 1051-1053.
50. Valencia I, Miles DK, Melvin J, et al. Relapse of herpes encephalitis after acyclovir therapy: Report of two new cases and review of the literature. Neuropediatrics 2004; 35: 371-376.
51. De Tiege X, Rozenberg F, Des Portes V, et al. Herpes simplex encephalitis relapses in children: Differentiation of two neurologic entities. Neurology 2003; 61: 241-243.
52. Kimberlin DW, Lin CY, Jacobs RF, et al. Safety and efficacy of high-dose intravenous acyclovir in the management of neonatal herpes simplex virus infections. Pediatrics 2001; 108: 230-238.
53. Mejias A, Bustos R, Ardura MI, Ramirez C, Sanchez PJ,. Persistence of herpes simplex virus DNA in cerebrospinal fluid of neonates with herpes simplex virus encephalitis. J Perinatol 2009; 29: 290-296.
54. Kimberlin DW, Jacobs RF, Weller S, et al. Pharmacokinetics and safety of extemporaneously compounded valacyclovir oral suspension in pediatric patients from 1 month through 11 years of age. Clin Infect Dis 2010; 50: 221-228.
55. Wilhelmus KR,. Therapeutic interventions for herpes simplex virus epithelial keratitis. Cochrane Database Syst Rev 2008: CD002898.
56. Collum LM, McGettrick P, Akhtar J, Lavin J, Rees PJ,. Oral acyclovir (Zovirax) in herpes simplex dendritic corneal ulceration. Br J Ophthalmol 1986; 70: 435-438.
57. Guess S, Stone DU, Chodosh J,. Evidence-based treatment of herpes simplex virus keratitis: A systematic review. Ocul Surf 2007; 5: 240-250.
58. Knickelbein JE, Hendricks RL, Charukamnoetkanok P,. Management of herpes simplex virus stromal keratitis: An evidence-based review. Surv Ophthalmol 2009; 54: 226-234.
59. Christophers J, Clayton J, Craske J, et al. Survey of resistance of herpes simplex virus to acyclovir in northwest England. Antimicrob Agents Chemother 1998; 42: 868-872.
60. Danve-Szatanek C, Aymard M, Thouvenot D, et al. Surveillance network for herpes simplex virus resistance to antiviral drugs: 3-year follow-up. J Clin Microbiol 2004; 42: 242-249.
61. Safrin S, Crumpacker C, Chatis P, et al. A controlled trial comparing foscarnet with vidarabine for acyclovir-resistant mucocutaneous herpes simplex in the acquired immunodeficiency syndrome. The AIDS Clinical Trials Group. N Engl J Med 1991; 325: 551-555.
62. Kopp T, Geusau A, Rieger A, Stingl G,. Successful treatment of an aciclovir-resistant herpes simplex type 2 infection with cidofovir in an AIDS patient. Br J Dermatol 2002; 147: 134-138.
63. Perkins N, Nisbet M, Thomas M,. Topical imiquimod treatment of aciclovir-resistant herpes simplex disease: Case series and literature review. Sex Transm Infect 2011; 87: 292-295.
64. Lascaux AS, Caumes E, Deback C, et al. Successful treatment of aciclovir and foscarnet resistant Herpes simplex virus lesions with topical imiquimod in patients infected with human immunodeficiency virus type 1. J Med Virol 2012; 84: 194-197.
65. Kleymann G, Fischer R, Betz UA, et al. New helicase-primase inhibitors as drug candidates for the treatment of herpes simplex disease. Nat Med 2002; 8: 392-398.
66. Himaki T, Masui Y, Chono K, et al. Efficacy of ASP2151, a helicase-primase inhibitor, against thymidine kinase-deficient herpes simplex virus type 2 infection in vitro and in vivo. Antiviral Res 2012; 93: 301-304.
67. Bacon TH, Levin MJ, Leary JJ, Sarisky RT, Sutton D,. Herpes simplex virus resistance to acyclovir and penciclovir after two decades of antiviral therapy. Clin Microbiol Rev 2003; 16: 114-128.